MAP Pharmaceuticals Initiates Phase 3 Clinical Trial In Patients With Migraine
The product is self-administered via a Tempo Inhaler (shown at left), a MAP Pharmaceuticals' product.
The inhaled DHE was well tolerated among study subjects. It decreased migraine-associated nausea and sensitivity to light and sound.
Right after I wrote this, I saw an article on My Migraine Connection about the same topic. You'll want to read it for more in depth information about this product.
MAP0004 Shows Promise for Aborting Migraines
Technorati Tags: DHE, medication, research, news, treatment, depression, migraines, chronic illness, health, somebody heal me
Subscribe to the Somebody Heal Me feed: Subscribe in a reader or subscribe by e-mail.
Content by Diana E. Lee.